A Comparison of The Effectiveness of Tegoprazan and Lansoprazole in Achieving Cure Rates in Patients With Bleeding Peptic Ulcers: A Double-Blind Randomized Trial

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to compare the effects of tegoprazan vs lansoprazole in healing bleeding peptic ulcers. It will also teach about the safety of both modalities. The main questions it aims to answer are: How does the effectiveness of Tegoprazan compare with Lansoprazole in two weeks of healing rate bleeding peptic ulcer patients in the Indonesian population? Researchers will compare the drug tegoprazan to lansoprazole with a double-blind randomized control to see their effect on healing bleeding peptic ulcers. Participants will: Take drug tegoprazan 50 mg OD or lansoprazole 30 mg OD every day for 2 weeks Endoscopic examination at the beginning before treatment and after completion of treatment within 2 weeks Record of their adverse effect occurrence

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Subjects diagnosed with upper gastrointestinal bleeding caused by peptic ulcer through gastroscopic examination

Locations
Other Locations
Indonesia
Atma Jaya Hospital
RECRUITING
Jakarta
Cipto Mangunkusumo National General Hospital
RECRUITING
Jakarta
Contact Information
Primary
Mario Steffanus MD
mario.steffanus@atmajaya.ac.id
+6281288002263
Time Frame
Start Date: 2025-05-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 162
Treatments
Experimental: Potassium Channel Acid Blocker
Each randomized patients will consume Tegoprazan 50 mg tab PO OD for 2 weeks
Active_comparator: Proton Pump Inhibitor
Each randomized patients will consume Lansoprazole 30 mg tab PO OD for 2 weeks
Related Therapeutic Areas
Sponsors
Leads: Mario Steffanus
Collaborators: Dr Cipto Mangunkusumo General Hospital

This content was sourced from clinicaltrials.gov